C-Path Receives $675,000 Award for FDA Collaboration
The Critical Path Institute(C-Path) has received $675,000 from the US Food and Drug Administration (FDA) for the first year of what is anticipated to be a multi-year, multi phased research program in cardiovascular disease.
额外的支持后续的年度大奖depend upon completion of the first year and additional Federal support, but could result in up to $2 million over three years to support a collaborative scientific and educational program with theUniversity of UtahandIntermountain Health Care.
The goal of this program is to advance the development of personalized medicines for patients with cardiovascular disease.
"This award will fund scientists to evaluate genetic tests that, when finally reviewed and accepted by the FDA, would enable pharmaceutical companies and physicians to improve the safe use of both old and new medicines for the treatment of heart failure," said Dr. Raymond Woosley, President & CEO of C-Path.
"We are pleased and excited to be working with C-Path and the University of Utah/Intermountain Health Care on this very important project, which has the potential to reduce the number of people who experience unwanted and sometimes dangerous side effects of their medicines," said Dr. Janet Woodcock, Deputy Commissioner of the FDA.
"This is exactly the kind of project that we envisioned when we established our collaborative relationship with C-Path."
"The external peer review group gave this project high marks because it brings together scientists from the FDA, C-Path, industry and academia to advance personalized medicine."
Dr. Jeffrey Anderson, Professor of Medicine at the University of Utah and Associate Chief of Cardiology at Intermountain Healthcare's LDS Hospital, said, "I am especially pleased to work on this project with scientists at the FDA and our collaborators at C-Path."
Dr. Woosley noted that "C-Path's goal is to improve the speed, efficiency and safety of medical product development."
"The genetic tests evaluated in this project should identify patients who are at risk for side effects and, in the future, enable the FDA to safely speed the availability of new drugs to patients who can benefit without being harmed."
